Anti-Mouse/Human CD49d (Clone PS/2) – Purified in vivo GOLD™ Functional Grade
Anti-Mouse/Human CD49d (Clone PS/2) – Purified in vivo GOLD™ Functional Grade
Product No.: C797
Clone PS/2 Target CD49D Formats AvailableView All Product Type Monoclonal Antibody Alternate Names VLA-4α, ITGA4, Integrin α4 Isotype Rat IgG2b κ Applications FA , FC , IHC , in vivo , IP |
Antibody DetailsProduct DetailsReactive Species Human ⋅ Mouse Host Species Rat Recommended Isotype Controls Recommended Dilution Buffer Immunogen P815 DBA/2 murine mastocytoma cells. Product Concentration ≥ 5.0 mg/ml Endotoxin Level <1.0 EU/µg as determined by the LAL method Purity ≥95% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day 2-8°C Applications and Recommended Usage? Quality Tested by Leinco FC Additional Applications Reported In Literature ? FA, IHC Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity PS/2 activity is directed against mouse CD49d and is cross reactive against human CD49d. Background Integrins are a large family of heterodimeric transmembrane molecules that mediate adhesion, migration, cell survival, and cell differentiation. CD49d is a single-pass type I membrane glycoprotein also known as integrin alpha-4 (Uniprot Accession P13612). CD49d is the α4 subunit of integrin heterodimers alpha-4/beta-1 (VLA-4; CD49d/CD29; α4β1 integrin) and alph-4/beta-7 (LPAM-1)1. These integrins act as receptors for fibronectin and VCAM1 (CD106). Integrin alpha-4/beta-7 is also a receptor for MADCAM1.
CD49d is expressed on most lymphocytes, granulocytes, monocytes, and thymocytes. CD49d/CD29 (VLA-4; α4β1) is expressed at high levels on the surface of lymphohematopoietic progenitors and is involved in their development and proliferation. CD49d/CD29 integrin/VCAM-1 interactions facilitate B cell adhesion to stromal cells and enhance B cell activation. In the absence of alpha-4 integrins, pre-B cells fail to transmigrate and proliferate. PS/2 recognizes murine and human CD49d2. PS/2 was generated by immunizing Fisher rats with P815 cells and subsequently fusing the spleen cells with Sp2/0. Hybridoma supernatants were screened by cell adhesion assay and cells producing blocking antibodies were cloned. Adhesion is blocked in a dose dependent manner when PS/2 is used with P815 and +/+ 2.4 stromal cells. 70Z/3 cells are also sensitive to PS/2 inhibition. PS/2 is known to block binding of CD49d to its ligands3. Lymphocyte production is completely blocked when PS/2 is included in Whitlock-Witte culture2. PS/2 is IgG2b κ. Antigen Distribution CD49d is expressed on T cells, B cells, NK , dendritic cells, thymocytes, monocytes, eosinophils, mast cells. Ligand/Receptor Fibronectin, VCAM-1, MAdCAM-1 Research Area Cell Adhesion . Cell Biology . Immunology . Innate Immunity Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. The clone PS/2 is widely used in in vivo mouse studies primarily as an antibody directed against mouse CD49d, also known as VLA-4 or Integrin α4. Common applications of this clone include:
In the literature, several antibodies and proteins are commonly used in conjunction with or discussed alongside PS/PT (anti-phosphatidylserine/prothrombin) antibodies. Here's an overview of relevant ones:
In summary, while PS2 and pS2 are not directly related to aPS/PT in clinical contexts, research involving aPS/PT often includes discussions about aβ2GpI, aCL, and LAC due to their relevance in APS diagnostics. Scientific literature citing clone PS/2 primarily refers to a well-established anti-CD49d (integrin alpha-4) monoclonal antibody widely used in immunology to study leukocyte adhesion, homing, and trafficking, particularly in mice and humans. Below are the key findings from its citations, synthesized from available information and established scientific context:
If you are seeking findings specifically from the antibody's own citation record (sometimes compiled by suppliers or database resources), these consistently emphasize its role as a tool for functional blocking of α4 integrin in both mouse and human systems, facilitating advancements in leukocyte biology, inflammation research, and translational immunotherapy. Should you need detailed citation metrics, lists of specific studies, or examples of particular disease model applications, let me know for a deeper breakdown. Dosing regimens for clone PS/2 anti-CD49d antibody vary significantly across different mouse models in terms of total dose, administration frequency, and duration. The primary factors influencing dosing include the mouse strain, age, and experimental purpose (e.g., leukocyte depletion vs. functional blockade). Key patterns and variations:
Factors influencing regimen selection:
General recommendations:
When designing a dosing regimen, consult both peer-reviewed literature and supplier protocols to tailor the strategy to your chosen mouse model, acknowledging that genetic background, age, and experimental design are significant variables. References & Citations1. Holzmann B, Weissman IL. EMBO J. 8(6):1735-1741. 1989.
2. Miyake K, Weissman IL, Greenberger JS, et al. J Exp Med. 173(3):599-607. 1991. 3. Andrew DP, Berlin C, Honda S, et al. J Immunol. 153(9):3847-3861. 1994. 4. Miyake K, Medina K, Ishihara K, et al. J Cell Biol. 114(3):557-565. 1991. 5. Enghofer M, Bojunga J, Ludwig R, et al. Am J Physiol. 274(5):E928-E935. 1998. 6. Hokibara S, Takamoto M, Isobe M, et al. Clin Exp Immunol. 114(2):236-244. 1998. 7. Fukuoka M, Fukudome K, Yamashita Y, et al. Blood. 96(13):4267-4275. 2000. 8. Omenetti S, Brogi M, Goodman WA, et al. Cell Mol Gastroenterol Hepatol. 1(4):406-419. 2015. 9. Chung KJ, Chatzigeorgiou A, Economopoulou M, et al. Nat Immunol. 18(6):654-664. 2017. 10. Tanneau GM, Hibrand-Saint Oyant L, Chevaleyre CC, et al. J Histochem Cytochem. 47(12):1581-1592. 1999. 11. Tchilian EZ, Owen JJ, Jenkinson EJ. Immunology. 92(3):321-327. 1997. 12. Liu ZJ, Tanaka Y, Fujimoto H, et al. J Immunol. 163(9):4901-4908. 1999. 13. Bellingan GJ, Xu P, Cooksley H, et al. J Exp Med. 196(11):1515-1521. 2002. 14. Bowden RA, Ding ZM, Donnachie EM, et al. Circ Res. 90(5):562-569. 2002. 15. Hirata T, Furie BC, Furie B. J Immunol. 169(8):4307-4313. 2002. 16. Maus UA, Srivastava M, Paton JC, et al. J Immunol. 173(2):1307-1312. 2004. 17. Eshghi S, Vogelezang MG, Hynes RO, et al. J Cell Biol. 177(5):871-880. 2007. 18. Li W, Ishihara K, Yokota T, et al. Glycobiology. 18(1):114-124. 2008. 19. Vaz R, Martins GG, Thorsteinsdóttir S, et al. Cell Tissue Res. 348(3):569-578. 2012. 20. Zhang Y, Chen YC, Krummel MF, et al. J Immunol. 189(8):3914-3924. 2012. 21. Sens C, Altrock E, Rau K, et al. J Bone Miner Res. 32(1):70-81. 2017. Technical ProtocolsCertificate of Analysis |
Formats Available
